Leap Therapeutics (FRA:5MC) Price-to-Operating-Cash-Flow : (As of Jun. 02, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Leap Therapeutics Price-to-Operating-Cash-Flow?

As of today (2025-06-02), Leap Therapeutics's share price is €0.262. Leap Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was €-1.35. Hence, Leap Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Leap Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

FRA:5MC's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.365
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Leap Therapeutics's Cash Flow from Operations per share for the three months ended in Mar. 2025 was €-0.33. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 was €-1.35.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 26.80% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 29.30% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 22.80% per year.

During the past 13 years, Leap Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 43.40% per year. The lowest was -63.70% per year. And the median was 22.55% per year.

Leap Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Leap Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics Price-to-Operating-Cash-Flow Chart

Leap Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Leap Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Leap Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Leap Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Leap Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Leap Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Leap Therapeutics's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Leap Therapeutics Price-to-Operating-Cash-Flow Calculation

Leap Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.262	/	-1.35
	=

Leap Therapeutics's Share Price of today is €0.262.
Leap Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.35.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Leap Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Leap Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (FRA:5MC) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

LPTX:USA 5MC:Germany

Address

47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141

Website

https://www.leaptx.com

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Leap Therapeutics Headlines

No Headlines